http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
SpringWorks Therapeutics Announces Executive Leadership Promotions
-
SpringWorks Therapeutics Announces Executive Leadership Promotions
-
SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference
-
SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference
-
SpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights
-
Jazz Pharmaceuticals (JAZZ) Acquires SpringWorks Therapeutics' (SWTX) FAAH Inhibitor Program
-
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
-
SpringWorks Therapeutics Inc. (SWTX), Pfizer Inc. (PFE) Report Clinical Collaboration to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myelom
-
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma
-
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma
-
SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
-
SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
-
Precision BioSciences (DTIL), SpringWorks Therapeutics (SWTX) Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple My
-
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
-
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
-
SpringWorks Therapeutics Inc. (SWTX) Enters Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as BCMA Potentiator in Multiple Myeloma
-
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
-
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
-
SpringWorks (SWTX) Announces Pact with COG to Conduct Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series
-
SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication
-
SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication
-
SpringWorks Therapeutics Inc. (SWTX) Announces Clinical Collaboration with Janssen (JNJ) to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myelo
-
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
-
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
-
SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
-
SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
-
SpringWorks Therapeutics Inc. (SWTX) Reports Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
-
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
-
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
-
BeiGene (BGNE) and SpringWorks (SWTX) Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clini
-
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
-
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
-
Allogene Therapeutics (ALLO), SpringWorks (SWTX) Therapeutics Report Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
-
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
-
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
